Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiretroviral therapy |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
1997
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AG03
|
| gptkbp:CASNumber |
gptkb:136817-59-9
|
| gptkbp:contraindication |
hypersensitivity to delavirdine
|
| gptkbp:discontinued |
gptkb:United_States
2017 |
| gptkbp:drugClass |
non-nucleoside reverse transcriptase inhibitor
|
| gptkbp:eliminationHalfLife |
5.8 hours
|
| gptkbp:genericName |
gptkb:delavirdine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rescriptor
|
| gptkbp:LegalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Pfizer
|
| gptkbp:metabolism |
liver
|
| gptkbp:MolecularFormula |
C22H23N7O2
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
gptkb:DB00705
10482054 54680686 |
| gptkbp:sideEffect |
nausea
headache rash |
| gptkbp:UNII |
Q1J8A4J6Z4
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:delavirdine
|
| gptkbp:bfsLayer |
6
|